文献速递慢性静脉疾病

非配制聚多卡醇1%静脉内微泡沫(Varithena)消融与静脉内热消融的疗效比较:系统评价与网状Meta分析

Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-04-26

本研究通过系统评价与网状Meta分析,比较聚多卡醇1%静脉内微泡沫消融与射频或激光静脉内热消融治疗下肢躯干静脉功能不全所致静脉功能不全的有效性与安全性。共纳入13项研究。结果显示,两者在静脉闭合率(OR 0.65,95%CI 0.36-1.18,P=0.16)和深静脉血栓风险上无统计学显著差异;聚多卡醇1%微泡沫的静脉闭合率显著优于医生配制泡沫(OR 2.91,95%CI 1.58-5.37,P<0.01)。

要点

  • 聚多卡醇1%微泡沫与热消融的静脉闭合率无统计学显著差异(OR 0.65,95%CI 0.36-1.18,P=0.16)。
  • 聚多卡醇1%微泡沫的静脉闭合率显著优于医生配制泡沫(OR 2.91,95%CI 1.58-5.37,P<0.01)。
  • 两种治疗的深静脉血栓风险无关联;静脉临床严重程度评分改善和溃疡愈合率数据不足,未能进行网状Meta分析。

核心结论

  • 基于已发表证据的网状Meta分析,聚多卡醇1%静脉内微泡沫与静脉内热消融在静脉闭合率和深静脉血栓风险上无统计学显著差异。
  • 聚多卡醇1%静脉内微泡沫与医生配制泡沫相比有统计学显著差异,静脉闭合的比值更高。
  • 敏感性分析显示,静脉闭合结果在随访12个月及以上、最长至6年时稳健。
  • 符合本综述纳入标准的新证据将定期纳入动态网状Meta分析。

研究设计与样本

  • 系统文献综述遵循最佳实践,包括前瞻性方案,检索2000年至2023年发表的英文随机和非随机研究。
  • 纳入报告聚多卡醇1%静脉内微泡沫与静脉内热消融直接或间接比较的研究,13项研究符合网状Meta分析纳入标准。
  • 共同主要有效性结局为术后≥3个月的闭合率和静脉临床严重程度评分的平均变化;静脉溃疡亚组的主要有效性结局为溃疡愈合率。
  • 次要结局包括安全性和患者报告结局;对数据充足的结局进行网状Meta分析。
  • 分类结局用比值比(OR)及95%置信区间(CI)汇总;使用敏感性检验和网络不一致性估计研究稳健性。

主要发现

  • 聚多卡醇1%静脉内微泡沫与静脉内热消融在静脉闭合方面无统计学显著差异(OR 0.65,95%CI 0.36-1.18,P=0.16)。
  • 聚多卡醇1%静脉内微泡沫与医生配制泡沫相比有统计学显著差异,静脉闭合的比值更高(OR 2.91,95%CI 1.58-5.37,P<0.01)。
  • 使用每项研究中最长可用闭合时间点(至少随访12个月,中位48个月,范围12-72个月)的敏感性分析显示结果与主分析相似。
  • 未发现深静脉血栓风险与所接受治疗之间存在关联。
  • 可用数据不足以对静脉临床严重程度评分改善和溃疡愈合率进行网状Meta分析。

关键数值与推荐

  • 静脉闭合:聚多卡醇1%静脉内微泡沫 vs 静脉内热消融,OR 0.65(95%CI 0.36-1.18,P=0.16),无统计学显著差异。
  • 静脉闭合:聚多卡醇1%静脉内微泡沫 vs 医生配制泡沫,OR 2.91(95%CI 1.58-5.37,P<0.01),聚多卡醇1%微泡沫比值更高。
  • 敏感性分析随访:至少12个月,中位48个月,范围12-72个月,结果与主分析相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We compared the effectiveness and safety of polidocanol 1% endovenous microfoam ablation vs endovenous thermal ablation with radiofrequency or laser energy for treatment of venous insufficiency caused by lower extremity truncal vein incompetence via network meta-analysis of published comparative evidence. METHODS: We conducted a systematic literature review following best practices, including a prospective protocol. We screened studies published in English from 2000 to 2023 for randomized and nonrandomized studies reporting direct or indirect comparisons between polidocanol 1% endovenous microfoam and endovenous thermal ablation. Thirteen studies met our eligibility criteria for the network meta-analysis. The co-primary effectiveness outcomes were the closure rate ≥3 months after procedure and the average change in the Venous Clinical Severity Score. For the subgroup of venous ulcer patients, the ulcer healing rate was the primary effectiveness outcome. The secondary outcomes included safety and patient-reported outcomes. Network meta-analyses were conducted on outcomes having sufficient data. Categorical outcomes were summarized using odds ratios (ORs) with 95% confidence intervals (CIs). Sensitivity tests and estimates of network inconsistency were used to investigate the robustness of our meta-analysis. RESULTS: We found that polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure (OR, 0.65; 95% CI, 0.36-1.18; P = .16). Although not the primary aim of the study, the network meta-analysis also provided evidence to confirm our supposition that polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds for vein closure (OR, 2.91; 95% CI, 1.58-5.37; P < .01). A sensitivity analysis using the longest available time point for closure in each study, with a minimum of 12 months of follow-up (median, 48 months; range, 12-72 months), showed results similar to those of the main analysis. No association was found between the risk of deep vein thrombosis and the treatment received. The available data were insufficient for a network meta-analysis of Venous Clinical Severity Score improvement and ulcer healing rates. CONCLUSIONS: Polidocanol 1% endovenous microfoam was not significantly different statistically from endovenous thermal ablation for venous closure and deep vein thrombosis risk for chronic venous insufficiency treatment, based on a network meta-analysis of published evidence. Polidocanol 1% endovenous microfoam was significantly differentiated statistically from physician-compounded foam, with higher odds of vein closure. A sensitivity analysis found venous closure findings were robust at follow-up intervals of 12 months or greater and for up to 6 years. New evidence meeting the inclusion criteria for this review will be incorporated at regular intervals into a living network meta-analysis.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Kabnick LS, Jimenez JC, Coogan SM, et al. Comparative effectiveness of non-compounded polidocanol 1% endovenous microfoam (Varithena) ablation versus endovenous thermal ablation utilizing a systematic review and network meta-analysis. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38679141. doi:10.1016/j.jvsv.2024.101896

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。